By Fineline Cube 
On October 11, 2025, the National Joint Procurement Office (NJPO) released the full company list for the 11th round of the National Organized Centralized Drug Procurement (VBP). The announcement confirmed that 396 companies successfully passed the information review and are now eligible to compete for the government‑designated volumes.
Key Highlights
| Item | Detail |
|---|---|
| Total Specified Demand | ~3.7 billion doses (≈ 75 % of the previously disclosed total volume) |
| Top‑Demand Drug | AstraZeneca’s Dapagliflozin – > 460 million tablets |
| Most Competitive Category | Diprophylline Injection – 48 companies bidding |
| Largest Multi‑Product Participant | Better Pharmaceutical – 17 product entries |
| New Entrants | 19 firms newly added to the competition |
| Unique Allocation | Ningxia Zhouyang Pharmaceutical received 1.5 million doses of Adenosylcobalamin; 18 companies remain unassigned |
Impact of Brand‑Independent Selection
The NJPO’s option for medical institutions to choose brands independently has boosted participation from foreign origin‑research companies. Big names such as AstraZeneca, Roche, Chugai Pharmaceutical, and Novartis now compete in the centralized procurement pool, adding depth and choice to the national supply chain.
What This Means for the Market
- Supply Chain Resilience – Near‑triple‑digit demand for Dapagliflozin signals robust market uptake for type‑2‑diabetes therapeutics.
- Competitive Pricing – The influx of 396 vendors is expected to drive price reductions and improve access across the country.
- Innovation Incentive – The inclusion of foreign origin‑research firms encourages technology transfer and local capacity building.
About the National Joint Procurement Office
The NJPO is the central agency responsible for coordinating nationwide drug procurement, ensuring the efficient allocation of critical medicines and fostering transparency in the pharmaceutical market.-Fineline Info & Tech